---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022877"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2026-05-14T12:05:15+00:00"
generated_at: "2026-05-14T12:21:46.723765+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M

## Summary
- Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
- GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).
- Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.
- Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test.

## SEC filing metadata
- accession: 0001493152-26-022877
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2026-05-14T12:05:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/0001493152-26-022877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022877
- JSON: https://secwatch.observer/filing/0001493152-26-022877.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.